Provided by Tiger Fintech (Singapore) Pte. Ltd.

LAVA Therapeutics N.V.

1.32
+0.04003.13%
Volume:151.64K
Turnover:201.86K
Market Cap:34.71M
PE:-1.30
High:1.38
Open:1.30
Low:1.28
Close:1.28
Loading ...

Company Profile

Company Name:
LAVA Therapeutics N.V.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
37
Office Location:
Yalelaan 62,Utrecht,Utrecht,Netherlands
Zip Code:
3584 CM
Fax:
- -
Introduction:
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Directors

Name
Position
Stephen Hurly
Management Director and Chief Executive Officer
Erik J. van den Berg
Non-Executive Director
Guido Magni
Non-Executive Director
Joel J. P. Jean Mairet
Non-Executive Director
Kapil Dhingra
Chairperson and Non-Executive Director
Karen J. Wilson
Non-Executive Director
Nanna Luneborg
Non-Executive Director
Stefan Luzi
Non-Executive Director

Shareholders

Name
Position
Stephen Hurly
Management Director and Chief Executive Officer
Edward F. Smith
Chief Financial Officer
Amy Garabedian
General Counsel and Corporate Secretary
Benjamin Winograd
Chief Medical Officer
Hans van der Vliet
Chief Scientific Officer
Paul Parren
EVP and Head of Research and Development
Ton Adang
Chief Development Officer